面向失代偿期肝硬化患者的教育与药物管理干预:随机对照试验研究方案
该研究方案拟在澳大利亚昆士兰州一家三级医院肝病门诊开展随机对照试验,将失代偿期肝硬化患者随机分配至临床药师主导的教育与药物管理干预组或常规照护组,在基线和约6个月随访时用经验证问卷评估用药依从性、药物信念、疾病感知与生活质量,并在52周收集患者结局数据。
要点
- 干预组在肝病医生常规随访基础上接受临床药师基线的教育与药物管理干预,并在随后6个月内再接受三次教育接触。
- 常规照护组由肝病医生按肝病门诊现行照护模式进行随访。
- 所有参与者在基线和约入组后6个月接受问卷调查,患者结局数据在52周收集。
核心结论
- 该方案描述的干预已可在全球肝病门诊照护中心调整和实施。
- 研究可能影响药物管理的可变因素以及临床药师主导的教育与药物管理干预对这些因素的改变作用,将为这些患者未来的管理提供有价值的信息。
研究设计与样本
- 一项在澳大利亚昆士兰州一家三级医院肝病门诊中心开展的随机对照试验。
- 同意的失代偿期肝硬化患者在常规随访就诊时被随机分配至教育干预组或常规照护组。
主要发现
- 常规照护组参与者由肝病医生按肝病门诊现行照护模式进行复查。
- 干预组参与者在基线由临床药师提供教育与药物管理干预,并同时接受肝病医生复查。
- 干预组参与者在随后6个月内还接受临床药师三次进一步教育接触,以及该时间段内安排的常规肝病医生复查。
- 所有参与者在基线和随访(约入组后6个月)时接受调查,使用经验证问卷工具确定用药依从性、药物信念、疾病感知和生活质量。
- 患者结局数据在52周收集。
关键数值与推荐
- 使用经验证问卷工具评估用药依从性、药物信念、疾病感知和生活质量。
- 通过调查、患者访谈和医疗记录获取患者对饮食和生活方式调整、当前用药及其他临床数据的知识。
临床怎么用
- 该方案描述的干预已可在全球肝病门诊照护中心调整和实施。
- 研究可能影响药物管理的可变因素以及临床药师主导的教育与药物管理干预对这些因素的改变作用,将为这些患者未来的管理提供有价值的信息。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People with decompensated cirrhosis require complex medical care and are often prescribed an intricate and frequently changing medication and lifestyle regimen. However, many patients mismanage their medications or have poor comprehension of their disease and self-management tasks. This can lead to harm, hospitalization, and death. METHODS/DESIGN: A patient-oriented education and medication management intervention has been developed for implementation at a tertiary hospital hepatology outpatient center in Queensland, Australia. Consenting patients with decompensated cirrhosis will be randomly allocated to education intervention or usual care treatment arms when they attend routine follow-up appointments. In the usual care arm, participants will be reviewed by their hepatologist according to the current model of care in the hepatology clinic. In the intervention arm, participants will be reviewed by a clinical pharmacist to receive the education and medication management intervention at baseline in addition to review by their hepatologist. Intervention participants will also receive three further educational contacts from the clinical pharmacist within the following 6-month period, in addition to routine hepatologist review that is scheduled within this time frame. All participants will be surveyed at baseline and follow-up (approximately 6 months post-enrollment). Validated questionnaire tools will be used to determine participant adherence, medication beliefs, illness perceptions, and quality of life. Patients' knowledge of dietary and lifestyle modifications, their current medications, and other clinical data will be obtained from the survey, patient interview, and medical records. Patient outcome data will be collected at 52 weeks. DISCUSSION: The intervention described within this protocol is ready to adapt and implement in hepatology ambulatory care centers globally. Investigation of potentially modifiable variables that may impact medication management, in addition to the effect of a clinical pharmacist-driven education and medication management intervention on modifying these variables, will provide valuable information for future management of these patients. TRIAL REGISTRATION: Australian and New Zealand Clinical Trial Registry identifier: ACTRN12616000780459 . Registered on 15 June 2016.
引用
- Hayward KL, Martin JH, Cottrell WN, et al. Patient-oriented education and medication management intervention for people with decompensated cirrhosis: study protocol for a randomized controlled trial. Trials. 2017. PMID: 28728560. doi:10.1186/s13063-017-2075-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。